Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat + Gemtuzumab Ozogamicin in RR-AML
NCT03848754Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pracinostat in acute myeloid leukemia (AML) (4 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Dose-Limiting Toxicity. Started May 2019; status: completed.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03848754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848754.